A clear new classification of prediabetes subtypes can help clinicians identify their most at-risk patients and aid in developing targeted therapies to prevent progression to diabetes, researchers report.
Glucagon to treat severe hypoglycemia is available in a generic formula for the first time in 20 years.
Newer classes of diabetes drugs reliably protect patients from heart and kidney damage associated with type 2 diabetes and chronic kidney disease, an American Heart Association analysis finds. Increased use may help the medical community kickstart stalled progress in treating these patients, the authors say.
Regular PPI users are 24% more likely to develop type 2 diabetes than non-users. What’s more, the longer participants use these drugs, the greater their risk, investigators have found.
Researchers have found new potential for a safe and widely used medication. The discovery could be “life-changing” for patients at risk of dementia, they say.
A large new study finds that people with type 2 diabetes have a 36% higher risk for vascular dementia when compared with people who do not have diabetes.
Isolation or living alone did not predispose study participants to diabetes, but loneliness due to poor-quality relationships did, investigators say.
New studies show evidence that common glucose-lowering drugs significantly lower the rate of kidney decline and death.
Bringing weight below an individualized “trigger” threshold could prevent or even reverse the disease, the results of a new study indicate.
Early combination therapy is now advised when glycemic control is not achieved within three months, and in patients with cardiovascular disease or chronic kidney disease.
